Accession Number:



Sensitization of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery

Descriptive Note:

Technical Report,15 Aug 2018,14 Aug 2019

Corporate Author:

Cedars-Sinai Medical Center Los Angeles United States

Personal Author(s):

Report Date:


Pagination or Media Count:



In the first year of this three-year project, we have completed tasks following the timeline of our Statement of Work. We synthesize large amount of HMCD-SIM, enough for the entire project. We determined therapeutic efficacy of the HMCD-SIM on pancreatic cancer cell lines and confirmed the sensitization function of the HMCD-SIM. We have established two new pancreatic cancer cell lines, and tested assay conditions for measuring GASP-1 in clinical serum samples. For mechanistic investigation, we have identified IC50 of the HMCD-SIM in combination with GEM and CDDP in BXPC-3 and MiaPaCa-2 cells. A series IHC analyses were conducted to determine the expression of OATPs on pancreatic cancer cell lines and tumor specimens. Throughout these analyses, OATP1B3 is determined to be a subject for further mutagenesis studies. These works laid a solid foundation for second year mechanistic investigation of the molecular mechanism of HMCD-SIM mediated cancer cell killing.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: